Literature DB >> 23115077

B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.

Francesco Maura1, Carlo Visco, Erika Falisi, Gianluigi Reda, Sonia Fabris, Luca Agnelli, Giacomo Tuana, Marta Lionetti, Nicola Guercini, Elisabetta Novella, Ilaria Nichele, Anna Montaldi, Francesco Autore, Anna Gregorini, Wilma Barcellini, Vincenzo Callea, Francesca R Mauro, Luca Laurenti, Robin Foà, Antonino Neri, Francesco Rodeghiero, Agostino Cortelezzi.   

Abstract

The development of autoimmune hemolytic anemia (AIHA) in patients with chronic lymphocytic leukemia (CLL) is associated with specific biological features. The occurrence of AIHA was hereby investigated in a retrospective series of 585 CLL patients with available immunoglobulin heavy chain variable (IGHV) gene status. AIHA occurred in 73 patients and was significantly associated with an IGHV unmutated (UM) status (P < 0.0001) and unfavorable [del(17)(p13) and del(11)(q23)] cytogenetic lesions (P < 0.0001). Stereotyped HCDR3 sequences were identified in 29.6% of cases and were similarly represented among patients developing or not AIHA; notably, subset #3 was associated with a significantly higher risk of AIHA than the other patients (P = 0.004). Multivariate analysis showed that UM IGHV, del(17)(p13) and del(11)(q23), but not stereotyped subset #3, were the strongest independent variables associated with AIHA. Based on these findings, we generated a biological risk score for AIHA development according to the presence of none (low risk), one (intermediated risk), or two (high risk) of the independent risk factors. Overall, our data indicate that UM IGHV status and/or unfavorable cytogenetic lesions are associated with the risk of developing secondary AIHA in CLL patients and suggest a possible role of specific stereotyped B-cell receptor subsets in a proportion of cases.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115077     DOI: 10.1002/ajh.23342

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Authors:  Quentin A Hill; Anita Hill; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-06-25

2.  Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Authors:  Paul J Hampel; Melissa C Larson; Brian Kabat; Timothy G Call; Wei Ding; Saad S Kenderian; Deborah Bowen; Justin Boysen; Susan M Schwager; Jose F Leis; Asher A Chanan-Khan; Eli Muchtar; Curtis A Hanson; Susan L Slager; Neil E Kay; Kari G Chaffee; Tait D Shanafelt; Sameer A Parikh
Journal:  Br J Haematol       Date:  2018-08-16       Impact factor: 6.998

Review 3.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

4.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528

5.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

6.  High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias.

Authors:  Donjete Simnica; Simon Schliffke; Christoph Schultheiß; Nicola Bonzanni; Lorenzo F Fanchi; Nuray Akyüz; Barbara Gösch; Christian Casar; Benjamin Thiele; Janina Schlüter; Ansgar W Lohse; Mascha Binder
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.